Warren Viricel

Founder at Mablink Bioscience

Health Technology

Profile

Warren Viricel is associated with Mablink Bioscience SAS as the Chief Scientific Officer since 2018.
He is also the founder of the company, which was established in the same year.

Warren Viricel active positions

Companies	Position	Start
Mablink Bioscience Mablink Bioscience Pharmaceuticals: MajorHealth Technology Mablink Bioscience is a biotechnology company based in Lyon, France that develops next-generation antibody-drug conjugates for the treatment of solid tumors. Mablink Bioscience's exclusive PSarlink™ platform is a unique stealth technology that "masks" the hydrophobicity of the cytotoxic drugs by adding a polysarcosine chain to the linker. The French company's pipeline is built on the topoisomerase-I inhibitor exatecan as a payload for current developments. Recently, the company announced the publication of a review article titled “Payload Diversification\: A Key Step in the Development of Antibody–Drug Conjugates” which reviews the history of the successes and failures in ADC payloads and takes a look at the new roads currently explored by the industry. The company was founded in 2018 by Warren Viricel and Jean-Guillaume Lafay, with Jean-Guillaume Lafay serving as CEO since then.	Founder	01/01/2018

All active positions of Warren Viricel

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Warren Viricel's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	1
Mablink Bioscience Mablink Bioscience Pharmaceuticals: MajorHealth Technology Mablink Bioscience is a biotechnology company based in Lyon, France that develops next-generation antibody-drug conjugates for the treatment of solid tumors. Mablink Bioscience's exclusive PSarlink™ platform is a unique stealth technology that "masks" the hydrophobicity of the cytotoxic drugs by adding a polysarcosine chain to the linker. The French company's pipeline is built on the topoisomerase-I inhibitor exatecan as a payload for current developments. Recently, the company announced the publication of a review article titled “Payload Diversification\: A Key Step in the Development of Antibody–Drug Conjugates” which reviews the history of the successes and failures in ADC payloads and takes a look at the new roads currently explored by the industry. The company was founded in 2018 by Warren Viricel and Jean-Guillaume Lafay, with Jean-Guillaume Lafay serving as CEO since then.	Health Technology